Get the Stockscreener App
1.88
5.03%
0.09
After Hours:
1.82
-0.06
-3.19%
Marker Therapeutics Inc stock is traded at $1.88, with a volume of 73,274.
It is up +5.03% in the last 24 hours and down -42.86% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
See More
Previous Close:
$1.79
Open:
$1.81
24h Volume:
73,274
Relative Volume:
1.12
Market Cap:
$20.13M
Revenue:
-
Net Income/Loss:
$-9.70M
P/E Ratio:
-1.7091
EPS:
-1.1
Net Cash Flow:
$-8.57M
1W Performance:
-10.05%
1M Performance:
-42.86%
6M Performance:
-57.18%
1Y Performance:
-61.00%
1-Day Range:
$1.7022
$1.89
1-Week Range:
$1.65
$2.1675
52-Week Range:
$1.65
$5.99
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.88 | 20.13M | 0 | -9.70M | -8.57M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Marker Therapeutics Announces Board Resignation - MSN
MRKR stock touches 52-week low at $1.8 amid market challenges - MSN
Marker Therapeutics Announces Board Resignation By Investing.com - Investing.com Nigeria
Marker Therapeutics pops on receiving $9.5M grant to advance lead asset - MSN
Hematopoietic Stem Cell Transplantation Market: Soaring - openPR
MRKR stock touches 52-week low at $2.4 amid challenging year - MSN
MRKR stock touches 52-week low at $2.4 amid challenging year By Investing.com - Investing.com South Africa
Marker Therapeutics (NASDAQ:MRKR) Shares Down 7.5% – What’s Next? - Defense World
SEC Form 424B3 filed by Marker Therapeutics Inc. - Quantisnow
BostonGene Evaluates Novel Therapies and Immune System Profiling as a Marker of Response in Patients with Gastrointestinal Cancers - Business Wire
BioZorb Lawuit LawyerBreast Biopsy Marker RecallJanuary 2025 Update - Levin Papantonio
MRKRMarker Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Marker Therapeutics director Steve Elms acquires $35,472 in stock By Investing.com - Investing.com Australia
Marker Therapeutics director Steve Elms acquires $35,472 in stock - Investing.com India
Sterling Bank shareholders approve its buyout by EverBank - Jacksonville Daily Record
Marker Therapeutics sees $1.77 million stock acquisition by investors By Investing.com - Investing.com Australia
Marker Therapeutics, Inc. announced that it expects to receive $16.1 million in funding - Marketscreener.com
Marker Therapeutics sells 5.03M shares at $3.20 in private placement - MSN
Marker Therapeutics reports promising lymphoma study results By Investing.com - Investing.com UK
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - GlobeNewswire
Marker Therapeutics Announces $16.1 Million Private Placement - GlobeNewswire
Marker Therapeutics Secures $16.1M Private Placement to Advance Lymphoma Cell Therapy Trial - StockTitan
Marker Therapeutics' MT-601 Shows 78% Response Rate in Lymphoma Trial, Promising Post-CAR-T Results - StockTitan
Marker Therapeutics pops on receiving $9.5M grant to advance lead asset (NASDAQ:MRKR) - Seeking Alpha
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer - The Manila Times
Marker Therapeutics receives $9.5 million grant for study - Investing.com
Marker Therapeutics Awarded $9.5 Million Grant from the - GlobeNewswire
Marker Therapeutics Secures $9.5M Grant to Advance Promising Pancreatic Cancer Treatment - StockTitan
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium - The Manila Times
Marker Therapeutics to Present at the 2024 Ladenburg - GlobeNewswire
Marker Therapeutics CEO to Present Latest Immunotherapy Innovations at Ladenburg Thalmann Oncology Symposium - StockTitan
Marker Therapeutics Leads 3 Noteworthy US Penny Stocks - Simply Wall St
Baylor College of Medicine-partnered Marker Therapeutics files for $11.4M offering - The Business Journals
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit - GlobeNewswire
Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study - MSN
Hematopoietic Stem Cell Transplantation Market to Exhibit - openPR
Silence Therapeutics' Zerlasiran Shows 90% Reduction in Key Heart Disease Marker | SLN Stock News - StockTitan
Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):